Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × durvalumab × Plasma cell × Clear all

Phase

Phase 1 3 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 129 Gastrointestinal 109 Genitourinary 38 Breast 27 Head & Neck 22 Gynecologic 18 Sarcoma 8 Other solid neoplasm 8 Dermatologic 7 Tumor-Agnostic 6 Lymphoid 4 CNS 4 Endocrine 3 Other hematologic neoplasm 2 Plasma cell 1 NET 1 Myeloid 1

Conditions

Recurrence 1 Multiple Myeloma 1

Interventions

Dexamethasone 335 Bortezomib 177 Lenalidomide 176 Cyclophosphamide 163 Melphalan 122 Calcium Dobesilate 103 daratumumab 95 pomalidomide 65 carfilzomib 64 fludarabine phosphate 60 Peripheral Blood Stem Cell Transplantation 59 Filgrastim 51 Thalidomide 50 Mycophenolic Acid 49 Busulfan 47 ixazomib 45 Whole-Body Irradiation 41 Tacrolimus 41 fludarabine 40 Granulocyte Colony-Stimulating Factor 40 dexamethasone acetate 32 Etoposide 30 Cyclosporine 29 Antilymphocyte Serum 29 isatuximab 28 dexamethasone 21-phosphate 26 auricularum 24 elotuzumab 23 Radiotherapy 23 Prednisone 23

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03000452 2018-10-16

FUSION-MM-005

Celgene

Phase 2 Completed

18 enrolled 16 charts

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡